Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > BUSINESS
BUSINESS
- Takeda Aims to Become No. 1 in Domestic Diabetes, Cardiovascular Markets: Senior Vice Pres. Iwasaki
September 27, 2012
- Novartis Obtains Approval for Low-Dose Xolair 75 mg
September 26, 2012
- Japan Vaccine Pres. Nagano Eyes One-Third Market Share or More in FY2020
September 26, 2012
- Kyorin Files NDA for Asthma Treatment KRP-108 in Japan
September 26, 2012
- Janssen Pharmaceutical Files for Once-Monthly Schizophrenia Treatment in Japan
September 26, 2012
- Kyowa Pharmaceutical Voluntarily Recalls Allopurinol Tablets 100 mg
September 25, 2012
- Sanofi-Aventis Looks to Clinical Evidence to Differentiate Lantus from Rival
September 25, 2012
- Equa Tops Both GP, HP Markets in August: RepTrack Survey
September 24, 2012
- Most Top Drugstore Chains Plan to Continue Dispensing Point Services After October
September 24, 2012
- Prasugrel Achieves Primary Endpoint in Domestic PIII Trial, Expects to Submit NDA in FY2013: Daiichi Sankyo
September 24, 2012
- Novartis to File for Additional Indication for Lucentis in Japan within This Year
September 24, 2012
- Pfizer Preparing for Assault on Domestic Generic Drug Market with Help from Mylan
September 24, 2012
- MTPC Launches Simponi in Indonesia
September 21, 2012
- Nichi-Iko to Set Up New Sections in Sales, Development Divisions to Enhance Oncology Field
September 21, 2012
- Nippon Shinyaku Files for Additional Indication of Chronic Pain for Tramal Capsule
September 21, 2012
- Chugai Applies for Avastin for Recurrent Glioblastoma
September 21, 2012
- Astellas, KEK Announce Collaboration to Develop New Drugs for NTDs
September 21, 2012
- Intellim Establishes Local Office in South Korea, Set to Realize Asian Studies
September 20, 2012
- TS-1 Shows Non-Inferiority to Gemcitabine in Effect on Resected Pancreatic Cancer: Taiho
September 20, 2012
- Symptoms of Cedar Pollen Allergy Reduced in PIII Trial for Sublingual Immunotherapy Drug: Torii
September 20, 2012
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…